Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
US11446303B2 · kind B2 · utility
1Cited by
12References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 17, 2020 |
| Grant date | Sep 20, 2022 |
| Priority date | — |
| Expiry date | Jun 17, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and/or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.